Hematology

New research reveals ruxolitinib’s hidden cholesterol risk in patients who have MPN and pelabresib’s durable benefit when added to ruxolitinib in myelofibrosis.

Reconstructed Kaplan-Meier data benchmark durability of CAR T-cell therapy, bispecific antibodies, and zanubrutinib combos for relapsed follicular lymphoma.

Adam Kittai, MD, reviews AMPLIFY data supporting acalabrutinib-venetoclax (AV) for CLL, citing strong safety and survival outcomes for select patients.

Emily K. Curran, MD, discusses how newer ALL therapies are reshaping treatment decisions and minimal residual disease monitoring for older adults.

New research reveals complex treatment costs from MM strain patients and caregivers during active therapy, while pain goes undertreated at end of life.

Independent investigations found that venetoclax-based combination regimens achieved high response and strong MRD negativity in newly diagnosed leukemias.

A Medicare claims analysis found zanubrutinib was associated with significantly longer treatment duration and overall survival vs acalabrutinib and ibrutinib.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

Community oncology practices are building bispecific programs in diverse configurations to retain patients and scale safely.

These phase 3 studies are evaluating outcomes among patients living with polycythemia vera, myelofibrosis, and essential thrombocythemia.

Current sickle cell disease (SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds, Julie Kanter, MD, says.

EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.

EHA 2026 highlights include advances in immunotherapy across blood cancers.

Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a manufacturing change.

Nipocalimab showed rapid responses within 1 week in warm autoimmune hemolytic anemia (wAIHA), as well as a favorable safety profile.

This new analysis offers some of the most rigorous real-world data to guide treatment decisions for TP53 wild-type chronic lymphocytic leukemia.

Baseline QOL is an independent prognostic factor for survival in AML, with global QOL carrying the largest HR, according to Fabio Efficace, PhD, MSc.

EHA 2026 late-breaking data featured phase 3 trials in CLL, AML, multiple myeloma, and myelofibrosis, plus early CAR T data in B-cell lymphoma and ITP.

Late-breaking phase 2 immunoPRISM trial data show teclistamab superior to Len/Dex in high-risk smoldering myeloma, with higher CR rates and PFS.

Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis.

In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.

As drug research globalizes, regulators and trial designers must collaborate across regions to bring new treatments to patients.

Replacing chemotherapy with blinatumomab improved event-free survival and reduced toxicity in high-risk pediatric ALL, data show.

The phase 3 frontMIND trial showed tafasitamab plus lenalidomide with R-CHOP reduced risk of disease progression or death in high-risk DLBCL.

Experts sparred over the feasibility and appropriateness of using minimal residual disease (MRD) to determine the duration of first-line CLL treatment.